Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HLA-C_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HLA-C_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HLA-C_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HLA-C_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HLA-C_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HLA-C_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HLA-C_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HLA-C_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HLA-C_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HLA-C_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HLA-C_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HLA-C_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HLA-C_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001988325 | Skin | AK | antigen processing and presentation of endogenous antigen | 8/1910 | 26/18723 | 3.36e-03 | 2.05e-02 | 8 |
GO:000248326 | Skin | AK | antigen processing and presentation of endogenous peptide antigen | 6/1910 | 19/18723 | 9.42e-03 | 4.60e-02 | 6 |
GO:0048002111 | Skin | SCCIS | antigen processing and presentation of peptide antigen | 13/919 | 62/18723 | 7.81e-06 | 2.86e-04 | 13 |
GO:0019882111 | Skin | SCCIS | antigen processing and presentation | 17/919 | 106/18723 | 1.52e-05 | 4.90e-04 | 17 |
GO:0019883112 | Skin | SCCIS | antigen processing and presentation of endogenous antigen | 7/919 | 26/18723 | 1.94e-04 | 3.69e-03 | 7 |
GO:0002483111 | Skin | SCCIS | antigen processing and presentation of endogenous peptide antigen | 6/919 | 19/18723 | 2.15e-04 | 4.02e-03 | 6 |
GO:001988227 | Skin | cSCC | antigen processing and presentation | 42/4864 | 106/18723 | 1.42e-03 | 8.98e-03 | 42 |
GO:000248327 | Skin | cSCC | antigen processing and presentation of endogenous peptide antigen | 11/4864 | 19/18723 | 3.17e-03 | 1.73e-02 | 11 |
GO:001988326 | Skin | cSCC | antigen processing and presentation of endogenous antigen | 13/4864 | 26/18723 | 7.35e-03 | 3.47e-02 | 13 |
GO:004800226 | Skin | cSCC | antigen processing and presentation of peptide antigen | 25/4864 | 62/18723 | 9.44e-03 | 4.25e-02 | 25 |
GO:00480026 | Stomach | GC | antigen processing and presentation of peptide antigen | 21/1159 | 62/18723 | 5.66e-11 | 1.10e-08 | 21 |
GO:00198826 | Stomach | GC | antigen processing and presentation | 25/1159 | 106/18723 | 4.82e-09 | 5.72e-07 | 25 |
GO:00024836 | Stomach | GC | antigen processing and presentation of endogenous peptide antigen | 9/1159 | 19/18723 | 6.79e-07 | 3.39e-05 | 9 |
GO:00198836 | Stomach | GC | antigen processing and presentation of endogenous antigen | 10/1159 | 26/18723 | 1.69e-06 | 7.67e-05 | 10 |
GO:00024746 | Stomach | GC | antigen processing and presentation of peptide antigen via MHC class I | 9/1159 | 28/18723 | 3.05e-05 | 8.43e-04 | 9 |
GO:00198856 | Stomach | GC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 7/1159 | 17/18723 | 3.84e-05 | 9.84e-04 | 7 |
GO:004800211 | Stomach | CAG with IM | antigen processing and presentation of peptide antigen | 21/1050 | 62/18723 | 8.88e-12 | 2.49e-09 | 21 |
GO:001988211 | Stomach | CAG with IM | antigen processing and presentation | 24/1050 | 106/18723 | 3.38e-09 | 3.53e-07 | 24 |
GO:000248311 | Stomach | CAG with IM | antigen processing and presentation of endogenous peptide antigen | 9/1050 | 19/18723 | 2.94e-07 | 1.78e-05 | 9 |
GO:001988311 | Stomach | CAG with IM | antigen processing and presentation of endogenous antigen | 10/1050 | 26/18723 | 6.86e-07 | 3.55e-05 | 10 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa042189 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa0414518 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
hsa0541618 | Breast | Precancer | Viral myocarditis | 14/684 | 60/8465 | 2.32e-04 | 1.98e-03 | 1.52e-03 | 14 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa052036 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0421814 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa0414519 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
hsa0541619 | Breast | Precancer | Viral myocarditis | 14/684 | 60/8465 | 2.32e-04 | 1.98e-03 | 1.52e-03 | 14 |
hsa0516619 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0516317 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0520312 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-C | SNV | Missense_Mutation | | c.575N>G | p.Leu192Arg | p.L192R | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
HLA-C | SNV | Missense_Mutation | novel | c.1008N>C | p.Lys336Asn | p.K336N | P10321 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.992) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | | c.376N>C | p.Asp126His | p.D126H | P10321 | protein_coding | deleterious_low_confidence(0.01) | benign(0.028) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HLA-C | SNV | Missense_Mutation | novel | c.493C>G | p.Gln165Glu | p.Q165E | P10321 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.984) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | rs11547351 | c.296G>C | p.Arg99Pro | p.R99P | P10321 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.98) | TCGA-VS-A9UR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HLA-C | SNV | Missense_Mutation | novel | c.349N>G | p.His117Asp | p.H117D | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | | c.425A>C | p.Tyr142Ser | p.Y142S | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HLA-C | SNV | Missense_Mutation | | c.773N>T | p.Arg258Met | p.R258M | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | rs281860353 | c.170N>C | p.Phe57Ser | p.F57S | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | rs281860449 | c.367N>C | p.Ser123Pro | p.S123P | P10321 | protein_coding | deleterious_low_confidence(0.01) | benign(0.174) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | flucloxacillin | FLOXACILLIN | 30664875 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | peginterferon alfa-2b | | |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | THERAPEUTIC TUMOR INFILTRATING LYMPHOCYTES | | 27959684 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | clavulanate | CLAVULANIC ACID | 30664875 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | amoxicillin | AMOXICILLIN | 30664875 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | Drugs For Treatment Of Tuberculosis | | 23153709 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | methotrexate | METHOTREXATE | 28444425 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | ribavirin | RIBAVIRIN | |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | ustekinumab | USTEKINUMAB | 23521149 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | clozapine | CLOZAPINE | 11266078 |